|
|
Stocks recovered dramatically from session lows yesterday, on higher volume. All five major indices closed lower on the session but well off their worst levels of the day. The S&P 500 contained losses to 0.5% after being as much as 1.2% down on the day. Read more…
Ron Rowland: In a few short hours we should have some big news: A Supreme Court decision on the constitutionality of health care reform. Investors have a lot at stake. Whatever the court decides will be good for some Health Care stocks Read more…
Stocks finished modestly higher on Tuesday, on mixed trade. All of the major exchanges ended the day higher, with the Nasdaq and S&P MidCap 400 leading the advance. Both indices closed up by 0.6%. The S&P 500 added 0.5%, while the small-cap Russell 2000 Read more…
Stocks posted solid gains on Friday but trade was light. All of the major indices closed in the black. The small-cap Russell 2000 demonstrated the most strength as it climbed 1.2% on the day. The Nasdaq posted a 1.0% gain, while the S&P MidCap 400 tacked on 0.9%. Read more…
Don Miller: Innovations in biotechnology are evolving at the speed of light. In fact, astonishing advancements in biotech have transformed the way we practice medicine. Leading-edge biotech products and breakthroughs are literally saving thousands of lives every day. Read more…
Michael Johnston: Despite some rather significant bumps along the road in 2011, many asset classes are now well into positive territory on a one year trailing basis as January draws to a close, riding high thanks to a strong finish to last year and start to 2012. Included on that list are a number of Read more…
March was the 10th anniversary of the beginning of the “tech wreck” when the NASDAQ peaked at 5132 on March 10, 2000. As we look back ten years and all that has transpired in technology and Read more…
NEW YORK (Reuters) – An experimental medicine from Dendreon Corp improved survival in men with advanced forms of prostate cancer, the company said on Tuesday, bolstering chances of it becoming the first approved therapeutic vaccine for any type of cancer.
Shares of Dendreon (DNDN.O) more than tripled in heavy morning trading to as high as $22.10 as the study results suggested a revolutionary form of therapy is on the horizon for one of the most common cancers. Unlike traditional vaccines that prevent disease, the company’s Provenge medicine treats it.
“If you’re in late stages of prostate cancer and your doctor says, ‘You’ll have no side effects with this drug and it will probably extend your life,’ who’s not going to take it?” said Sven Borho, an analyst with OrbiMed Advisors.
The Phase III clinical trial met the main study goal of improving survival, prompting Dendreon to say it will seek U.S. regulatory approval of Provenge in the fourth quarter.
“The successful outcome from the Phase 3 IMPACT study provides validation of the long-pursued goal of harnessing the human immune system against a patient’s own cancer,” Dendreon Chief Executive Mitchell Gold said in a statement.
Prostate cancer is the most common cancer in American men other than skin cancers, according to the American Cancer Society. About one in six men will be diagnosed with prostate cancer during his lifetime.
Full Story: http://www.reuters.com/article/hotStocksNews/idUSTRE53D4AB20090414
Most Comments